ArticleFrontiers in pediatrics2026
Case Report: Hepatoblastoma with spindle cell sarcomatous metastasis in a 14-year-old girl.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatoblastoma (HB) is the most common pediatric liver malignancy and occurs predominantly in children younger than 5 years of age. We report the case of a 14-year-old girl who was diagnosed with mixed epithelial-mesenchymal hepatoblastoma without any metastases. Initial evaluation revealed a markedly elevated serum alpha-fetoprotein level (7,800 ng/mL) and a large hepatic mass (17.3 cm × 18.4 cm × 8.5 cm) in the left liver lobe on contrast-enhanced CT. The patient underwent surgical resection, and pathological examination confirmed mixed epithelial-mesenchymal HB. Postoperative chemotherapy (consisting of cisplatin, doxorubicin, and 5-FU) normalized serum alpha-fetoprotein levels; however, skull metastasis developed during treatment. Histopathological analysis of the metastatic lesion revealed spindle cell sarcoma with decreased GPC-3/Hepa expression and elevated CD34/Ki-67 expression. Multiple chemotherapy regimens (ifosfamide, carboplatin, and etoposide; and doxorubicin, vincristine, cyclophosphamide, and cisplatin) demonstrated limited efficacy. Subsequent treatment with alternating albumin-paclitaxel, gemcitabine, ifosfamide, and etoposide/cyclophosphamide, irinotecan, and vincristine chemotherapy combined with anlotinib and cranial radiotherapy achieved disease stabilization, with no subsequent progression observed during follow-up. This case highlights the aggressive nature and chemoresistance of the mesenchymal components of HB, emphasizing the need for novel therapeutic approaches that incorporate targeted agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.